First clinical Dose of vaccine against coronavirus, but wont be available for widespread use.
Seatle, Washington observed its first first phase I clinical trial for a potential COVID-19 vaccine. Four patients received first clinical dose of vaccine at the Kaiser Permanente research facility. Researchers at the Kaiser Permanente Washington Research Institute in Seattle carried forward its first clinical trial with a cautious jab in a healthy volunteer’s arm. The achievement is remarkable, since it is the first vaccine developed in a record-beating time period after the novel virus emerged.
“We’re team coronavirus now,” Kaiser Permanente study leader Dr Lisa Jackson said on the eve of the experiment. “Everyone wants to do what they can in this emergency.”
The Associated Press news agency watched as the study’s first participant, an operations manager at a small tech company, received the injection inside an exam room. Several others were next in line for a test that will ultimately give 45 volunteers two doses, a month apart.
“We all feel so helpless. This is an amazing opportunity for me to do something,” said Jennifer Haller, 43, of Seattle.
She’s the mother of two teenagers and “they think it’s cool” that she’s taking part in the study.
Monday’s milestone marked just the beginning of a series of studies in people needed to prove whether the shots are safe and could work. Even if the research goes well, a vaccine would not be available for widespread use for 12 to 18 months, said Dr Anthony Fauci of the US National Institutes of Health.
That is still important if the virus becomes a long-term threat.
This vaccine candidate, code-named mRNA-1273, was developed by the NIH and Massachusetts-based biotechnology company Moderna Inc. There is no chance participants could become infected from the shots because they do not contain coronavirus itself.
It’s not the only potential vaccine in the pipeline. Dozens of research groups around the world are racing to create a vaccine against COVID-19. Another candidate, made by Inovio Pharmaceuticals, is expected to begin its own safety study – in the US, China and South Korea – next month.
The Seattle experiment got under way days after the World Health Organization declared the new virus outbreak a pandemic because of its rapid global spread, infecting more than 169,000 people and killing more than 6,500.
The novel coronavirus has upended the world’s social and economic fabric since China first identified the virus last year, with regions shuttering schools and businesses, restricting travel, cancelling entertainment and sporting events, and encouraging people to stay away from each other.
Starting what scientists call a first-in-humans study is a momentous occasion for scientists, but Jackson described her team’s mood as “subdued”.
They have been working around the clock, preparing the research in a part of the US that was struck early and hard by the virus.
Still, “going from not even knowing that this virus was out there … to have any vaccine” in testing in about two months is unprecedented, Jackson told The Associated Press.
Some of the study’s carefully chosen healthy volunteers, ages 18 to 55, will get higher dosages than others to test how strong the inoculations should be. Scientists will check for any side effects and draw blood samples to test if the vaccine is revving up the immune system, looking for encouraging clues like the NIH earlier found in vaccinated mice.
“We don’t know whether this vaccine will induce an immune response, or whether it will be safe. That’s why we’re doing a trial,” Jackson stressed. “It’s not at the stage where it would be possible or prudent to give it to the general population.”
Most of the vaccine research under way globally targets a protein aptly named “spike” that studs the surface of the new coronavirus and lets it invade human cells. Block that protein and people will not get infected.
Researchers at the NIH copied the section of the virus’s genetic code that contains the instructions for cells to create the spike protein. Moderna encased that “messenger RNA” into a vaccine.
The idea: The body will become a mini-factory, producing some harmless spike protein. When the immune system spots the foreign protein, it will make antibodies to attack – and be primed to react quickly if the person later encounters the real virus.
That is a much faster way of producing a vaccine than the traditional approach of growing virus in the lab and preparing shots from either killed or weakened versions of it.
But because vaccines are given to millions of healthy people, it takes time to test them in large enough numbers to spot an uncommon side effect, cautioned Dr Nelson Michael of the Walter Reed Army Institute of Research, which is developing a different vaccine candidate.
“The science can go very quickly but, first, do no harm, right?” he told reporters last week.
The Seattle research institute is part of a government network of centres that test all kinds of vaccines, and was chosen for the coronavirus vaccine study before COVID-19 began spreading widely in Washington state.
Kaiser Permanente screened dozens of people, looking for those who have no chronic health problems and are not currently sick. Researchers are not checking whether would-be volunteers already had a mild case of COVID-19 before deciding if they are eligible.
If some did, scientists will be able to tell by the number of antibodies in their pre-vaccination blood test and account for that, Jackson said. Participants will be paid $100 for each clinic visit in the study.
Make sure you are subscribed to the TechonBio. You can also get latest information on more interesting developments in the biotechnology industry.
A technophile who is crazy about technology and passionate about blogging.
I care by sharing recent advancements in technology and try to reach out to the minds of people